左旋门冬酰胺酶治疗难治性中线外周T细胞淋巴瘤  

The efficacy of L asparaginase in the treatment of refractory midline peripheral T cell lymphoma

作　　者：勇威本[1] 张运涛[1] 郑文[1] 卫燕[1] 朱军[1] 

机构地区：[1]北京医科大学临床肿瘤学院,北京肿瘤医院,100036

出　　处：《中华血液学杂志》2000年第11期577-579,共3页Chinese Journal of Hematology

摘　　要：目的　提高难治性中线外周T细胞淋巴瘤 (MPTCL)的疗效。方法　左旋门冬酰胺酶 (L ASP)组为 11例难治性MPTCL患者 ,给予L ASP为主的挽救化疗 (由L ASP、长春新碱和地塞米松组成 )。对照组为 10例难治性MPTCL患者 ,给予不含L ASP的联合化疗。观察比较两组的有效率和 2年生存率。结果　有效 (完全缓解加部分缓解 )率L ASP组为 6 3 .6 % ,对照组为 10 .0 % (P <0 .0 5 )。 2年生存率L ASP组为 45 .5 % ,对照组为 0 (P <0 .0 5 )。本组L ASP治疗的不良反应主要表现为白细胞减少、血清胆红素升高和高血糖症。结论　L ASP为主的挽救化疗可能提高难治性MPTCL的疗效和 2年生存率 ,值得进一步研究。Objective To improve the treatment outcome of refractory midline peripheral T cell lymphoma (MPTCL). Method Eleven patients with refractory MPTCL received salvage chemotherapy consisting of L asparaginase(L ASP), vincristine and dexamethosone (L ASP group), and 10 patients received combined chemotherapy without L ASP(control group). The response rates and 2 year survival rates were observed. Results Response rates were 63 6% for L ASP group and 10.0% for control group (P<0.05), and 2 year survival rates were 45 5% and 0 (P<0.05), respectively. The major side effects of L ASP were leukocytopenia, elevation of serum bilirubin and hyperglycemia. Conclusion The L ASP based salvage chemotherapy improved the response rate and 2 year survival rate of the patients with refractory MPTCL.

关 键 词：左旋门冬酰胺酶 淋巴瘤 中线外周T细胞 药物疗法 

分 类 号：R733.405[医药卫生—肿瘤]